Market closedNon-fractional
Athira Pharma/ATHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Athira Pharma
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Ticker
ATHA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Bothell, United States
Employees
66
Website
www.athira.com
Athira Pharma Metrics
BasicAdvanced
$98M
Market cap
-
P/E ratio
-$3.05
EPS
2.92
Beta
-
Dividend rate
Price and volume
Market cap
$98M
Beta
2.92
Financial strength
Current ratio
5.025
Quick ratio
4.833
Long term debt to equity
1.047
Total debt to equity
1.403
Management effectiveness
Return on assets (TTM)
-42.67%
Return on equity (TTM)
-73.11%
Valuation
Price to book
0.92
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-0.968
Growth
Earnings per share change (TTM)
12.52%
3-year earnings per share growth
31.12%
What the Analysts think about Athira Pharma
Analyst Ratings
Majority rating from 6 analysts.
Athira Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$26M
-3.31%
Profit margin
0.00%
NaN%
Athira Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.78
-$0.87
-$0.71
-$0.69
-
Expected
-$0.78
-$0.81
-$0.96
-$0.79
-$0.73
Surprise
-0.40%
6.88%
-26.02%
-12.71%
-
Athira Pharma News
AllArticlesVideos
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
GlobeNewsWire·3 weeks ago
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
PRNewsWire·4 weeks ago
Athira Pharma to Participate in Upcoming June Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Athira Pharma stock?
Athira Pharma (ATHA) has a market cap of $98M as of July 06, 2024.
What is the P/E ratio for Athira Pharma stock?
The price to earnings (P/E) ratio for Athira Pharma (ATHA) stock is 0 as of July 06, 2024.
Does Athira Pharma stock pay dividends?
No, Athira Pharma (ATHA) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Athira Pharma dividend payment date?
Athira Pharma (ATHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Athira Pharma?
Athira Pharma (ATHA) has a beta rating of 2.92. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Athira Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.